[Federal Register Volume 68, Number 78 (Wednesday, April 23, 2003)]
[Notices]
[Page 20014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-9960]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Circulatory System Devices Panel of the Medical Devices Advisory 
Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Circulatory System Devices Panel of the Medical 
Devices Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 29, 2003, from 9 
a.m. to 5 p.m.
    Location: Gaithersburg Holiday Inn, Walker/Whetstone Rooms, Two 
Montgomery Village Ave., Gaithersburg, MD.
    Contact Person: Geretta Wood, Center for Devices and Radiological 
Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., 
Rockville, MD 20850, 301-443-8320, ext. 143, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 12625. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: The committee will hear a presentation on postmarket 
surveillance of diathermy interactions with implanted leads and 
implanted systems with leads. The committee will also discuss, make 
recommendations, and vote on a premarket approval application for an 
ablation catheter for treatment of atrial fibrillation in patients with 
drug refractory paroxysmal atrial fibrillation. Background information 
for the topic, including the agenda and questions for the committee, 
will be available to the public 1 business day before the meeting on 
the Internet at http://www.fda.gov/cdrh/panelmtg.html. Material will be 
posted on May 28, 2003.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by May 15, 2003. 
Oral presentations from the public will be scheduled for approximately 
30 minutes at the beginning of committee deliberations and for 
approximately 30 minutes near the end of the deliberations. Time 
allotted for each presentation may be limited. Those desiring to make 
formal oral presentations should notify the contact person before May 
15, 2003, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact AnnMarie Williams, 
Conference Management Staff, at 301-594-1283, ext. 113, at least 7 days 
in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 15, 2003.
Lester M. Crawford,
Deputy Commissioner.
[FR Doc. 03-9960 Filed 4-22-03; 8:45 am]
BILLING CODE 4160-01-S